Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT), a commercial-stage biotechnology company with a market capitalization of $446.4 million specializing in mRNA therapeutics and vaccines, stands at a ...
Arcturus Therapeutics Holdings Inc. (the "Company", "Arcturus", Nasdaq: ARCT), a commercial messenger RNA medicines company ...
Arcturus Therapeutics Holdings Inc is a biotechnology firm based in San Diego, California, specializing in the development of innovative mRNA medicines and vaccines. With a focus on addressing ...
Zacks.com on MSN3d
Axsome (AXSM) Surges 20.2%: Is This an Indication of Further Gains?Axsome (AXSM) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings ...
Collectively, these elements underscore Arcturus Therapeutics’ capacity for innovation and market penetration, justifying the Buy rating. ARCT’s price has also changed moderately for the past ...
BTIG initiated coverage of Arcturus Therapeutics (ARCT) with a Buy rating and $41 price target Arcturus is a commercial-stage biotechnology ...
NASDAQ:ARCT opened at $16.84 on Tuesday. Arcturus Therapeutics has a 1 year low of $14.30 and a 1 year high of $45.00. The stock has a 50-day moving average price of $17.26 and a two-hundred day ...
Providing a diverse range of perspectives from bullish to bearish, 5 analysts have published ratings on Arcturus Therapeutics (NASDAQ:ARCT) in the last three months. The table below summarizes ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback